Our current results thus suggest the possible future use of NUFS‐sErt to manage CNS metastases in EGFR‐mutant lung cancer patients, particularly in cases that are not responsive to osimertinib or experience progression after an initial response to radiotherapy. Here, EGFR is linked to lung carcinoma.